MAP 315 / Microba - LARVOL DELTA

A study to evaluate the safety, tolerability and pharmacokinetics of MAP 315 in healthy adults (ANZCTR) - P1 | N=32 | Completed | Sponsor: Microba Pty Ltd | Active, not recruiting ➔ Completed

Trial completion • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A study to evaluate the safety, tolerability and pharmacokinetics of MAP 315 in healthy adults (ANZCTR) - P1 | N=32 | Active, not recruiting | Sponsor: Microba Pty Ltd | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Trial initiation date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Microba Commences Phase I Clinical Trial for IBD Therapeutic (Businesswire) - "Microba Life Sciences Limited...announces that the first participants have been successfully dosed in the Phase I Clinical Trial of MAP 315, in Microba’s Therapeutic Program in Inflammatory Bowel Disease (IBD). This milestone brings Microba’s drug candidate MAP 315 into clinical development as a potential new treatment option for the millions of people suffering from ulcerative colitis....The Phase I clinical trial is a randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of MAP 315 in 32 healthy adults....The study will enroll 2 cohorts of 16 participants each, who will be randomised 3:1 to receive MAP 315 or its matching placebo for 14 consecutive days (2 weeks). Results from the trial are expected to be available in December 2023."

P1 data • Trial status